GlassScriptPhysician profile
Jannat Kang
NPI 1801404363
$1,833.79
in general payments reported to CMS, 2019-2025
19 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.48 · 2021: $36.57 · 2023: $459 · 2024: $778 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $431.24 | 2023-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $181.49 | 2020-2025 | Wegovy, Sogroya, Ozempic |
| Corcept Therapeutics | $178.33 | 2023-2025 | Korlym |
| Dexcom, INC. | $131.15 | 2023-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $114.74 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $105.98 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Kyowa Kirin, INC. | $99.15 | 2024-2025 | Crysvita |
| Lilly USA, LLC | $99.12 | 2023-2025 | Mounjaro, Zepbound, Humulin |
| Mallinckrodt Hospital Products INC. | $88.13 | 2024 | Terlivaz |
| Recordati_rare_diseases_inc. | $62.73 | 2024-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $61.24 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Ascendis Pharma Endocrinology INC | $53.63 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $53.25 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $45.75 | 2024 | |
| Janssen Pharmaceuticals, INC | $36.57 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $25.88 | 2025 | Qutenza |
| Rhythm Pharmaceuticals, INC. | $25.56 | 2025 | Imcivree |
| Pfizer INC. | $22.53 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jannat Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.